- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapies in gastric cancer and future perspectives
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 2, Pages 471
Publisher
Baishideng Publishing Group Inc.
Online
2016-01-18
DOI
10.3748/wjg.v22.i2.471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
- (2015) Ramesh K. Ramanathan et al. CANCER
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin-like growth factor 1 promotes growth of gastric cancer by inhibiting foxo1 nuclear retention
- (2015) Shuangling Li et al. TUMOR BIOLOGY
- Novel CD9-targeted therapies in gastric cancer
- (2015) Yoko Murayama et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
- (2015) H Liu et al. Cell Death & Disease
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review
- (2015) Kyle A. Beckwith et al. Frontiers in Physiology
- The role of HER3 in gastric cancer
- (2014) Liying Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH
- (2014) Kakoli Das et al. CANCER LETTERS
- Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
- (2014) R. Salgia et al. CLINICAL CANCER RESEARCH
- Panitumumab safety for treating colorectal cancer
- (2014) Stefan Stremitzer et al. Expert Opinion On Drug Safety
- Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
- (2014) Hidemi Kawajiri et al. Expert Review of Anticancer Therapy
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
- (2014) Zhi Peng et al. PLoS One
- The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
- (2014) Oscar Tapia et al. VIRCHOWS ARCHIV
- Ramucirumab: preclinical research and clinical development
- (2014) Giuseppe Aprile et al. OncoTargets and Therapy
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
- (2013) Manfred Welslau et al. CANCER
- Pertuzumab: Optimizing HER2 Blockade
- (2013) O. Metzger-Filho et al. CLINICAL CANCER RESEARCH
- Claudins and gastric carcinogenesis
- (2013) Omid Iravani et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
- (2013) K.-W. Lee et al. INVESTIGATIONAL NEW DRUGS
- Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
- (2013) Su Jin Lee et al. INVESTIGATIONAL NEW DRUGS
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
- (2013) Sang Y Ha et al. MODERN PATHOLOGY
- Unknown
- (2013) Myra Barginear et al. MOLECULAR MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
- (2013) H. E. Uronis et al. ONCOLOGIST
- Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
- (2013) YORIKO YAMASHITA-KASHIMA et al. ONCOLOGY REPORTS
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer
- (2013) Jiahong Wang et al. PLoS One
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
- (2012) J H Yi et al. BRITISH JOURNAL OF CANCER
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
- (2012) Haruyasu Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
- (2012) Jan Trøst Jørgensen et al. Journal of Cancer
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
- (2011) Taekyu Lim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium
- (2011) Helen J. Mackay et al. INVESTIGATIONAL NEW DRUGS
- Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
- (2011) Maria D. Begnami et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
- (2011) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
- (2010) B. F. El-Rayes et al. ANNALS OF ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
- (2010) C. Ralph et al. CLINICAL CANCER RESEARCH
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
- (2009) S-W Han et al. BRITISH JOURNAL OF CANCER
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A novel therapeutic strategy with anti-CD9 antibody in gastric cancers
- (2009) Taisei Nakamoto et al. JOURNAL OF GASTROENTEROLOGY
- Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
- (2009) Tim P. Green et al. Molecular Oncology
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer
- (2008) J. Matsubara et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now